Valeant Pharmaceuticals International, Inc. (VRX) PT Raised to $17.00

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX) had its target price raised by BMO Capital Markets from $16.00 to $17.00 in a research note issued to investors on Monday. BMO Capital Markets currently has a market perform rating on the specialty pharmaceutical company’s stock.

A number of other research analysts have also recently weighed in on the company. Vetr upgraded Valeant Pharmaceuticals International from a buy rating to a strong-buy rating and set a $14.26 target price on the stock in a report on Thursday, October 19th. ValuEngine cut Valeant Pharmaceuticals International from a buy rating to a hold rating in a report on Friday, September 1st. Royal Bank Of Canada reduced their target price on Valeant Pharmaceuticals International from $21.00 to $18.00 and set a sector perform rating on the stock in a report on Friday, October 20th. Wells Fargo & Company dropped coverage on Valeant Pharmaceuticals International in a research note on Sunday, July 30th. Finally, Cantor Fitzgerald restated a buy rating and set a $23.00 price objective on shares of Valeant Pharmaceuticals International in a research note on Tuesday, August 29th. Five research analysts have rated the stock with a sell rating, eleven have given a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. Valeant Pharmaceuticals International has an average rating of Hold and a consensus price target of $17.17.

Shares of Valeant Pharmaceuticals International (VRX) traded up $0.40 during trading on Monday, reaching $14.74. The company had a trading volume of 8,218,831 shares, compared to its average volume of 17,922,115. Valeant Pharmaceuticals International has a 52-week low of $8.31 and a 52-week high of $18.65. The firm has a market capitalization of $5,090.00, a PE ratio of 2.35, a P/E/G ratio of 0.40 and a beta of -0.40. The company has a quick ratio of 1.03, a current ratio of 1.26 and a debt-to-equity ratio of 4.84.

ILLEGAL ACTIVITY NOTICE: This piece was originally published by Community Financial News and is owned by of Community Financial News. If you are accessing this piece on another site, it was stolen and reposted in violation of United States and international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.com-unik.info/2017/11/17/valeant-pharmaceuticals-international-inc-vrx-pt-raised-to-17-00.html.

In related news, Director Schutter Richard U. De purchased 10,000 shares of the company’s stock in a transaction on Monday, August 21st. The shares were bought at an average price of $14.33 per share, with a total value of $143,300.00. Following the completion of the acquisition, the director now owns 77,479 shares of the company’s stock, valued at $1,110,274.07. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 5.87% of the stock is currently owned by corporate insiders.

A number of large investors have recently made changes to their positions in VRX. Riggs Asset Managment Co. Inc. raised its stake in Valeant Pharmaceuticals International by 118.2% during the 3rd quarter. Riggs Asset Managment Co. Inc. now owns 8,330 shares of the specialty pharmaceutical company’s stock valued at $119,000 after purchasing an additional 4,512 shares during the period. PNC Financial Services Group Inc. increased its stake in shares of Valeant Pharmaceuticals International by 33.7% in the first quarter. PNC Financial Services Group Inc. now owns 10,965 shares of the specialty pharmaceutical company’s stock worth $121,000 after acquiring an additional 2,763 shares during the last quarter. Financial Architects Inc increased its stake in shares of Valeant Pharmaceuticals International by 10.5% in the second quarter. Financial Architects Inc now owns 10,550 shares of the specialty pharmaceutical company’s stock worth $183,000 after acquiring an additional 1,000 shares during the last quarter. Cetera Investment Advisers acquired a new position in shares of Valeant Pharmaceuticals International in the second quarter worth $192,000. Finally, IPG Investment Advisors LLC acquired a new position in shares of Valeant Pharmaceuticals International in the second quarter worth $203,000. 46.61% of the stock is currently owned by institutional investors.

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Analyst Recommendations for Valeant Pharmaceuticals International (NYSE:VRX)

What are top analysts saying about Valeant Pharmaceuticals International Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Valeant Pharmaceuticals International Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit